From the Editor

Targeted sessions for targeted therapies at ASCO


 

It’s likely that you have just returned from ASCO 2014 in Chicago with 33,000 of your closest oncology friends, or that you have at least heard all about the meeting and some of the exciting presentations. Either way, you must be wondering how best to sift through the mountain of data and information that came out of the meeting so that you can organize it, absorb it, and here’s the real challenge, apply it in the real-clinic setting going forward.

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

VIDEO: New option arises for young women with hormone-sensitive breast cancer
MDedge Hematology and Oncology
VIDEO: ASCO 2014 roundtable on breast cancer research
MDedge Hematology and Oncology
Cochrane review: Trastuzumab benefit outweighs harm for advanced HER2-positive breast cancer
MDedge Hematology and Oncology
ALTTO: Dual HER2 blockade offers no survival edge in adjuvant breast cancer treatment
MDedge Hematology and Oncology
Single-agent paclitaxel fails in noninferiority trial for primary breast cancer
MDedge Hematology and Oncology
ASCO endorses "no ink on tumor" guidelines for breast cancer surgery
MDedge Hematology and Oncology
Frail women less likely to initiate hormonal therapy for breast cancer
MDedge Hematology and Oncology
Phone-based intervention helped breast cancer patients lose weight, but key question remains
MDedge Hematology and Oncology
Combined imaging differentiated benign, cancerous breast tumors
MDedge Hematology and Oncology
Adding tomosynthesis improved mammography’s cancer detection
MDedge Hematology and Oncology